These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 30425525)

  • 1. The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis.
    Peng M; Li X; Lei G; Weng YM; Hu MX; Song QB
    Onco Targets Ther; 2018; 11():7369-7383. PubMed ID: 30425525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Yan X; Tian X; Wu Z; Han W
    Front Oncol; 2020; 10():1671. PubMed ID: 33072551
    [No Abstract]   [Full Text] [Related]  

  • 3. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
    Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
    Front Oncol; 2022; 12():978069. PubMed ID: 36330494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
    Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
    JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Xu Y; Wang Q; Xie J; Chen M; Liu H; Zhan P; Lv T; Song Y
    Front Oncol; 2021; 11():732214. PubMed ID: 34557415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review.
    Ma X; Zhang Y; Wang S; Wei H; Yu J
    J Cancer; 2021; 12(5):1318-1333. PubMed ID: 33531977
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials.
    Liu CQ; Tian D; Wang N; Meng XP; Yang JD; Li HW; Zhao N; Zhao S; Liao F; Cui Y
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e81-e87. PubMed ID: 29071806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of the Efficacy and Tolerability of Immune Checkpoint Inhibitors Combined With Chemotherapy in First-line Treatment of Small Cell Lung Cancer.
    Wu J; Zhang A; Li L; Liu S; Yang F; Yang R
    Clin Ther; 2021 Mar; 43(3):582-593.e2. PubMed ID: 33509647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians.
    Peng S; Ying AF; Tai BC; Soo RA
    Transl Lung Cancer Res; 2020 Aug; 9(4):1124-1137. PubMed ID: 32953491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
    Tsukada A; Morita C; Shimizu Y; Uemura Y; Naka G; Takasaki J; Nokihara H; Izumi S; Hojo M
    Thorac Cancer; 2024 Sep; 15(25):1854-1862. PubMed ID: 39086088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer.
    Gao G; Qiao M; Liu H; Jiang T; Zhou F; Li X; Zhao C; Chen X; Su C; Ren S; Zhou C
    J Thorac Dis; 2019 Sep; 11(9):3794-3807. PubMed ID: 31656652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
    Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
    Front Oncol; 2022; 12():753234. PubMed ID: 35280736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
    Wu Y; Shi H; Jiang M; Qiu M; Jia K; Cao T; Shang Y; Shi L; Jiang K; Wu H
    Int J Cancer; 2017 Dec; 141(12):2562-2570. PubMed ID: 28833119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy.
    Pradeep J; Win TT; Aye SN; Sreeramareddy CT
    J Cancer; 2022; 13(10):3091-3102. PubMed ID: 36046644
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.
    Park R; Lopes L; Cristancho CR; Riano IM; Saeed A
    Front Oncol; 2020; 10():258. PubMed ID: 32257944
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials.
    Zhang L; Sun L; Zhou Y; Yu J; Lin Y; Wasan HS; Shen M; Ruan S
    Front Oncol; 2021; 11():575457. PubMed ID: 33718135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Tao L; Zhang H; An G; Lan H; Xu Y; Ge Y; Yao J
    Front Oncol; 2021; 11():739263. PubMed ID: 34722290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 20. Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials.
    Takada K; Shimokawa M; Mizuki F; Takamori S; Takenaka T; Miura N; Shikada Y; Yoshizumi T
    Eur J Med Res; 2022 Aug; 27(1):157. PubMed ID: 35999618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.